Pressure overload induces greater hypertrophy and mortality in female mice with p38alpha MAPK inhibition.

[1]  P. Wolf,et al.  Heart disease and stroke statistics--2006 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. , 2006, Circulation.

[2]  Masahiro Ito,et al.  Akt3 overexpression in the heart results in progression from adaptive to maladaptive hypertrophy. , 2005, Journal of molecular and cellular cardiology.

[3]  J. Miyazaki,et al.  Mitogen-Activated Protein Kinase Plays a Critical Role in Cardiomyocyte Survival but Not in Cardiac Hypertrophic Growth in Response to Pressure Overload , 2004 .

[4]  S. Vatner,et al.  Silent Information Regulator 2&agr;, a Longevity Factor and Class III Histone Deacetylase, Is an Essential Endogenous Apoptosis Inhibitor in Cardiac Myocytes , 2004, Circulation research.

[5]  R. Karas,et al.  17&bgr;-Estradiol Reduces Cardiomyocyte Apoptosis In Vivo and In Vitro via Activation of Phospho-Inositide-3 Kinase/Akt Signaling , 2004, Circulation research.

[6]  P. Doevendans,et al.  Targeted Inhibition of p38 Mitogen-activated Protein Kinase Antagonizes Cardiac Injury and Cell Death Following Ischemia-Reperfusion in Vivo* , 2004, Journal of Biological Chemistry.

[7]  K. Nakao,et al.  Androgen contributes to gender-related cardiac hypertrophy and fibrosis in mice lacking the gene encoding guanylyl cyclase-A. , 2004, Endocrinology.

[8]  J. Molkentin,et al.  Redefining the roles of p38 and JNK signaling in cardiac hypertrophy: dichotomy between cultured myocytes and animal models. , 2003, Journal of molecular and cellular cardiology.

[9]  Anthony J. Muslin,et al.  Role of 14-3-3-Mediated p38 Mitogen-Activated Protein Kinase Inhibition in Cardiac Myocyte Survival , 2003, Circulation research.

[10]  A. Dart,et al.  Sex hormones and cardiomyopathic phenotype induced by cardiac beta 2-adrenergic receptor overexpression. , 2003, Endocrinology.

[11]  Jing Liu,et al.  Disruption of type 5 adenylyl cyclase gene preserves cardiac function against pressure overload , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[12]  L. Leinwand,et al.  Sex is a potent modifier of the cardiovascular system. , 2003, The Journal of clinical investigation.

[13]  Timothy E Hewett,et al.  Targeted inhibition of p38 MAPK promotes hypertrophic cardiomyopathy through upregulation of calcineurin-NFAT signaling. , 2003, The Journal of clinical investigation.

[14]  A. Rosenzweig,et al.  Akt and PI 3-Kinase Signaling in Cardiomyocyte Hypertrophy and Survival , 2003, Cell cycle.

[15]  Attila Kovacs,et al.  The role of the Grb2-p38 MAPK signaling pathway in cardiac hypertrophy and fibrosis. , 2003, The Journal of clinical investigation.

[16]  B. Hoit,et al.  Differential regulation of p38 mitogen-activated protein kinase mediates gender-dependent catecholamine-induced hypertrophy. , 2003, Cardiovascular research.

[17]  J. Ross,et al.  Akt induces enhanced myocardial contractility and cell size in vivo in transgenic mice , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[18]  Charles Kooperberg,et al.  Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. , 2002, JAMA.

[19]  J. Rouleau,et al.  Elevated mean arterial pressure in the ovariectomized rat was normalized by ETA receptor antagonist therapy: absence of cardiac hypertrophy and fibrosis , 2002, British journal of pharmacology.

[20]  S. Cook,et al.  Phenotypic Spectrum Caused by Transgenic Overexpression of Activated Akt in the Heart* , 2002, The Journal of Biological Chemistry.

[21]  Mark A. Magnuson,et al.  Oestrogen protects FKBP12.6 null mice from cardiac hypertrophy , 2002, Nature.

[22]  H. Hense,et al.  Gender-specific differences of cardiac remodeling in subjects with left ventricular dysfunction: a population-based study. , 2002, Cardiovascular research.

[23]  H. Wellens,et al.  17&bgr;-Estradiol Attenuates the Development of Pressure-Overload Hypertrophy , 2001, Circulation.

[24]  J. Robbins,et al.  Matters of sex: sex matters. , 2001, Circulation.

[25]  A. Clerk,et al.  Akt like a woman: gender differences in susceptibility to cardiovascular disease. , 2001, Circulation research.

[26]  Mark A Sussman,et al.  Myocardial Akt Activation and Gender: Increased Nuclear Activity in Females Versus Males , 2001, Circulation research.

[27]  E. Giardina.  Heart disease in women. , 2000, International journal of fertility and women's medicine.

[28]  W. Sessa,et al.  Membrane Estrogen Receptor Engagement Activates Endothelial Nitric Oxide Synthase via the PI3-Kinase–Akt Pathway in Human Endothelial Cells , 2000, Circulation research.

[29]  K. Ley,et al.  Interaction of oestrogen receptor with the regulatory subunit of phosphatidylinositol-3-OH kinase , 2000, Nature.

[30]  J. Klein,et al.  Suppression by Metallothionein of Doxorubicin-induced Cardiomyocyte Apoptosis through Inhibition of p38 Mitogen-activated Protein Kinases* , 2000, The Journal of Biological Chemistry.

[31]  J. Gardin,et al.  Predictors of congestive heart failure in the elderly: the Cardiovascular Health Study. , 2000, Journal of the American College of Cardiology.

[32]  C. Hayward,et al.  The roles of gender, the menopause and hormone replacement on cardiovascular function. , 2000, Cardiovascular research.

[33]  E. Vittinghoff,et al.  Postmenopausal Hormone Therapy Increases Risk for Venous Thromboembolic Disease: The Heart and Estrogen/progestin Replacement Study , 2000, Annals of Internal Medicine.

[34]  D. Gardner,et al.  Mechanical strain activates BNP gene transcription through a p38/NF-kappaB-dependent mechanism. , 1999, The Journal of clinical investigation.

[35]  M. Kostkiewicz,et al.  Left ventricular geometry and function in patients with aortic stenosis: gender differences. , 1999, International journal of cardiology.

[36]  C. Grohé,et al.  Differential effects of 17[3‐estradiol on mitogen‐activated protein kinase pathways in rat cardiomyocytes , 1999, FEBS letters.

[37]  R. Virmani,et al.  Apoptosis in heart failure: release of cytochrome c from mitochondria and activation of caspase-3 in human cardiomyopathy. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[38]  P. Douglas,et al.  Gender differences in molecular remodeling in pressure overload hypertrophy. , 1999, Journal of the American College of Cardiology.

[39]  P. Douglas,et al.  Hypertrophic remodeling: gender differences in the early response to left ventricular pressure overload. , 1998, Journal of the American College of Cardiology.

[40]  E. Vittinghoff,et al.  Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. , 1998, JAMA.

[41]  A. Lin,et al.  Opposing Effects of Jun Kinase and p38 Mitogen-Activated Protein Kinases on Cardiomyocyte Hypertrophy , 1998, Molecular and Cellular Biology.

[42]  M. Diaz-Meco,et al.  The Activation of p38 and Apoptosis by the Inhibition of Erk Is Antagonized by the Phosphoinositide 3-Kinase/Akt Pathway* , 1998, The Journal of Biological Chemistry.

[43]  J Ross,et al.  Cardiac Muscle Cell Hypertrophy and Apoptosis Induced by Distinct Members of the p38 Mitogen-activated Protein Kinase Family* , 1998, The Journal of Biological Chemistry.

[44]  H. S. Kim,et al.  Hypertension, cardiac hypertrophy, and sudden death in mice lacking natriuretic peptide receptor A. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[45]  W. Haley,et al.  Gender dimorphism in cardiac adaptation to hypertension is unveiled by prior treatment and efficacy. , 1996, The American journal of cardiology.

[46]  S. Daniels,et al.  Gender differences in left ventricular growth. , 1995, Hypertension.

[47]  O. Hess,et al.  Sex-dependent differences in left ventricular function and structure in chronic pressure overload. , 1995, European heart journal.

[48]  J. Gardin,et al.  Relationship of cardiovascular risk factors to echocardiographic left ventricular mass in healthy young black and white adult men and women. The CARDIA study. Coronary Artery Risk Development in Young Adults. , 1995, Circulation.

[49]  C. Otto,et al.  Gender differences in left ventricle geometry and function in patients undergoing balloon dilatation of the aortic valve for isolated aortic stenosis. NHLBI Balloon Valvuloplasty Registry. , 1995, British heart journal.

[50]  P. Buttrick,et al.  Effects of sex hormones on development of physiological and pathological cardiac hypertrophy in male and female rats. , 1990, The American journal of physiology.

[51]  D. Levy,et al.  Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. , 1990, The New England journal of medicine.

[52]  A. M. Cabral,et al.  Sex Hormone Modulation of Ventricular Hypertrophy in Sinoaortic Denervated Rats , 1988, Hypertension.

[53]  W. Kannel,et al.  Menopause and Coronary Heart Disease: The Framingham Study , 1978 .

[54]  G. Moe,et al.  Akt signaling pathway in pacing-induced heart failure , 2005, Molecular and Cellular Biochemistry.

[55]  C. Otto,et al.  Gender differences in left ventricular function at rest and with exercise in asymptomatic aortic stenosis. , 1996, American heart journal.

[56]  R. Becker,et al.  Cardiovascular disease in women: facts and statistics. , 1995, Cardiology.

[57]  G. Aurigemma,et al.  Gender differences in older patients with pressure-overload hypertrophy of the left ventricle. , 1995, Cardiology.

[58]  P. Pantaleo,et al.  Influence of age and sex on left ventricular anatomy and function in normals. , 1992, Cardiology.